Table 4.
Association between clinicopathological characteristics and SUVmax
| (n) | SUVmax (mean ± SD)a | p valuea | |
|---|---|---|---|
| Tumour invasive sizeb (mm) (n = 57) | < 10 (20) | 4.9 ± 5.0 | 0.211 |
| 10–20 (25) | 8.5 ± 5.8 | ||
| > 20 (12) | 12.6 ± 11.0 | ||
| ER (%) | Negative (19) | 20.9 ± 11.5 | 0.0001 |
| Positive (65) | 9.0 ± 7.9 | ||
| HER2 | Negative (68) | 11.0 ± 9.8 | 0.149 |
| Positive (16) | 15.2 ± 11.3 | ||
| NG | 1 (52) | 8.4 ± 7.7 | 0.0001 |
| 2 (11) | 10.2 ± 8.9 | ||
| 3 (21) | 20.5 ± 11.1 | ||
| Ki67 (%) | < 20 (30) | 6.5 ± 5.0 | 0.0002 |
| ≥ 20 (54) | 14.7 ± 11.1 |
dbPET, dedicated breast positron emission tomography; HER2, human epidermal growth factor receptor 2; WBPET/MRI, whole-body positron emission tomography/magnetic resonance imaging; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; NG, nuclear grade; ER, oestrogen receptor
aANOVA, t test
bThe size was confirmed by surgical specimens and the excluded tumours received neoadjuvant chemotherapy